Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Filgotinib→

Filgotinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1206161-97-8
Molecular formula
C21H23N5O3S
Molecular weight
425.5 g/mol
Drug class
Preferential Janus kinase 1 (JAK1) inhibitortargeted synthetic immunomodulator
Mechanism of action
ATP-competitive and reversible inhibitor of the JAK family, with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2. This reduces phosphorylation and activation of STAT transcription factors downstream of multiple inflammatory cytokine receptors.
Indications / reported uses
  • Treatment of moderate-to-severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; monotherapy or in combination with methotrexate
  • Treatment of moderately-to-severely active ulcerative colitis in adults after inadequate response, loss of response or intolerance to conventional or biological therapy; use is subject to product-specific warnings and eligibility restrictions

Sources: EMA EPAR — Jyseleca · EMA product information — Jyseleca · UK SmPC — Jyseleca 100 mg · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Preferential Janus kinase 1 (JAK1) inhibitor; targeted synthetic immunomodulator

Mechanism of action

ATP-competitive and reversible inhibitor of the JAK family, with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2. This reduces phosphorylation and activation of STAT transcription factors downstream of multiple inflammatory cytokine receptors.

General use cases

  • Treatment of moderate-to-severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; monotherapy or in combination with methotrexate
  • Treatment of moderately-to-severely active ulcerative colitis in adults after inadequate response, loss of response or intolerance to conventional or biological therapy; use is subject to product-specific warnings and eligibility restrictions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Filgotinib Environmental Risk Assessment (ERA) (the Filgotinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.